

( (S (NP-SBJ Two major drug companies)
     (VP posted
         (NP strong third-quarter earnings)
         ,
         (PP in
             (NP (NP line)
                 (PP with
                     (NP (NP (NP profits)
			     (VP (ADVP-TMP already)
				 reported
				 (NP *)
				 (PP by
				     (NP-LGS industry leaders))))
			 and
			 (NP (NP analysts ')
			     expectations))))))
     .))
( (S But
     (NP-SBJ (NP Pfizer Inc.)
             ,
             (VP based
                 (NP *)
                 (PP-LOC-CLR in
			     (NP New York)))
             ,)
     (VP reported
         (NP flat earnings))
     .))
( (S (NP-SBJ (NP Schering-Plough Corp.)
             ,
             (VP based
                 (NP *)
                 (PP-LOC-CLR in
			     (NP (NP Madison)
				 ,
				 (NP N.J.)
				 ,))))
     (VP reported
         (NP (NP a (ADJP 21 %) rise)
	     (PP-LOC in
		     (NP earnings)))
	 (SBAR-ADV as
		   (S (NP-SBJ (NP American Home Products Corp.)
			      (PP of
				  (NP New York)))
		      (VP posted
			  (NP (NP an (ADJP 11 %) increase)
			      (PP-LOC in
				      (NP net)))))))
     .))
( (NP American Home Products))
( (S (NP-SBJ American Home Products)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP sales and earnings)
                          (PP for
			      (NP (NP the third quarter)
				  and
				  (NP nine months))))
                  (VP were
                      (PP-LOC-PRD at
				  (NP record levels))))))
     .))
( (S (NP-SBJ (NP Sales)
             (PP for
                 (NP the third quarter)))
     (VP increased
         (NP-EXT 6.5 %)
         (PP-DIR to
		 (NP (QP $ 1.51 billion) *U*))
         (PP-DIR from
		 (NP (QP $ 1.42 billion) *U*)))
     .))
( (S (NP-SBJ (NP Sales)
             (PP of
                 (NP health-care products)))
     (VP increased
         (NP-EXT 6 %)
         (PP-TMP in
		 (NP the third quarter))
	 ,
	 (PP based
	     (PP in
		 (NP part))
	     (PP on
		 (NP (NP (NP strong sales)
			 (PP of
			     (NP (NP prescription drugs)
				 (PP such as
				     (NP (NP Premarin)
					 ,
					 (NP an estrogen-replacement drug)
					 ,)))))
		     and
		     (NP (NP sales)
			 (PP of
			     (NP (NP the company 's)
				 infant formula)))))))
     .))
( (S (NP-SBJ American Home Products)
     (VP said
         (SBAR 0
               (S (NP-SBJ net income)
                  (VP benefited
                      (PP-CLR from
			      (NP (NP (NP a `` lower effective tax rate)
				      , 
				      ''
				      (VP reflecting
					  (NP (NP a reduction)
					      (PP of
						  (NP foreign tax rates)))))
				  , 
				  and
				  (NP (NP additional operations)
				      (PP-LOC in
					      (NP Puerto Rico)))))))))
     .))
( (S (NP-SBJ-1 Net)
     (ADVP also)
     (VP was
         (VP aided
             (NP *-1)
             (PP by
                 (NP-LGS (NP a gain)
			 (PP on
			     (NP (NP the sale)
				 (PP of
				     (NP (NP (NP the company 's)
					     equity interests)
					 (PP-LOC in
						 (NP South Africa))))))
			 (ADJP effective
			       (NP-TMP Sept. 1))))))
     .))
( (S (PP-LOC In
	     (NP New York Stock Exchange composite trading))
     (NP-TMP yesterday)
     ,
     (NP-SBJ American Home Products)
     (VP closed
         (PP-CLR at
		 (NP (NP $ 102.25 *U*)
		     (NP-ADV a share)))
         ,
         (ADVP down
	       (NP 75 cents)))
     .))
( (NP Pfizer))
( (S (NP-SBJ Pfizer)
     (VP said
         (SBAR 0
               (S (NP-SBJ third-quarter sales)
                  (VP increased
                      (NP-EXT 4 %)
                      (PP-DIR to
			      (NP (QP $ 1.44 billion) *U*))
                      (PP-DIR from
			      (NP (QP $ 1.38 billion) *U*))))))
     .))
( (S (NP-SBJ The company)
     (VP said
         (SBAR 0
               (S (NP-SBJ net income)
                  (VP was
                      (ADJP-PRD flat)
		      (PP-PRP because of
			      (NP (NP (NP investment)
				      (PP in
					  (NP research and development)))
				  and
				  (NP (NP costs)
				      (ADJP related
					    (PP to
						(NP (NP launches)
						    (PP of
							(NP several products))))))))))))
     .))
( (S (NP-SBJ The company)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the dollar 's)
                          continued strengthening)
                  (VP reduced
                      (NP world-wide sales growth)
                      (PP-EXT by
			      (NP three percentage points))))))
     .))
( (S (NP-SBJ Pfizer)
     (VP posted
         (NP (NP its largest gains)
             (PP-LOC in
		     (NP (NP (NP healthcare sales)
			     ,
			     (ADVP up
				   (NP 3 %))
			     ,)
			 and
			 (NP (NP consumer products)
			     ,
			     (ADVP up
				   (NP 23 %)))))))
     .))
( (S (S (NP-SBJ (NP Sales)
                (PP by
                    (NP the specialty chemicals and materials science segments)))
        (VP were
            (ADJP-PRD flat)))
     , 
     and
     (S (NP-SBJ (NP sales)
                (PP by
                    (NP the agriculture segment)))
        (VP declined
            (NP-EXT 5 %)))
     .))
( (S (PP-LOC In
	     (NP the health-care segment))
     ,
     (S (NP-SBJ pharmaceutical sales)
        (VP increased
            (NP-EXT 4 %)))
     and
     (S (NP-SBJ (NP sales)
                (PP of
                    (NP hospital products)))
        (VP increased
            (NP-EXT 1 %)))
     .))
( (S (PP-TMP During
	     (NP the quarter))
     ,
     (NP-SBJ Pfizer)
     (VP received
         (NP (NP federal approval)
             (PP of
                 (NP (NP (NP Procardia XL)
                         ,
                         (NP (NP a calcium channel blocker)
                             (VP approved
                                 (NP *)
                                 (PP-CLR for
					 (NP both angina and hypertension))))
                         ,)
                     and
                     (NP (NP Monorail Piccolino)
                         ,
                         (VP used
			     (NP *)
                             (S-CLR (NP-SBJ *)
				    (VP to
					(VP open
					    (NP obstructed coronary arteries))))))))))
     .))
( (S (PP-LOC In
	     (NP New York Stock Exchange composite trading))
     (NP-TMP yesterday)
     ,
     (NP-SBJ Pfizer)
     (VP closed
         (PP-CLR at
		 (NP (NP $ 67.75 *U*)
		     (NP-ADV a share)))
         ,
         (ADVP up
	       (NP 75 cents)))
     .))
( (NP Schering-Plough))
( (S (NP-SBJ Schering-Plough)
     (VP said
         (SBAR 0
               (S (NP-SBJ sales)
                  (VP gained
                      (NP 2.7 %)
                      (PP-DIR to
			      (NP (QP $ 743.7 million) *U*))
                      (PP-DIR from
			      (NP (QP $ 724.4 million) *U*))))))
     .))
( (S (PP-TMP In
	     (NP the period))
     ,
     (NP-SBJ the company)
     (VP (VP completed
             (NP (NP the sale)
                 (PP of
                     (NP its European cosmetics businesses))))
         ,
         (VP sold
             (NP (NP a majority interest)
                 (PP in
		     (NP its Brazilian affiliate))))
         , 
	 and
         (VP announced
             (NP (NP the reorganization)
                 (PP of
                     (NP its over-the-counter drug businesses))
                 (PP into
                     (NP (NP a new unit)
                         ,
                         (NP Schering-Plough Health Care Products))))))
     .))
( (S (NP-SBJ These actions)
     (VP did n't
         (VP affect
             (NP results)
	     (SBAR-PRP because
		       (S (NP-SBJ-1 (NP the gain)
				    (PP on
					(NP (NP the sale)
					    (PP of
						(NP the European cosmetics businesses)))))
			  (VP was
			      (VP offset
				  (NP *-1)
				  (PP by
				      (NP-LGS (NP provisions)
					      (VP relating
						  (PP-CLR to
							  (NP the 
							      (NX (NX Brazil divestiture)
								  and
								  (NX drug restructuring)))))))))))))
     .))
( (S (NP-SBJ-1 U.S. pharmaceutical sales)
     (VP rose
         (NP-EXT 15 %)
	 ,
	 (S-ADV (NP-SBJ-2 *-1)
		(VP led
		    (NP *-2)
		    (PP by
			(NP-LGS (NP allergy , asthma and cold products)
				;
				(NP dermatological products)
				;
				(NP (NP anti-infectives)
				    and 
				    (NP anti-cancer products))
				;
				and
				(NP cardiovascular products))))))
     .))
( (S (NP-SBJ World-wide consumer product sales)
     (VP declined
         (NP-EXT 12 %)
         ,
         (PP-PRP (ADVP primarily)
		 because of
		 (NP the European cosmetics sale)))
     .))
( (S (NP-SBJ (NP (ADJP Significantly lower)
		 sales)
             (PP of
                 (NP ` Stay Trim ' diet aids)))
     (ADVP also)
     (VP were
         (NP-PRD (NP a factor)
		 (PP-LOC in
			 (NP the drop))))
     .))
( (S (NP-SBJ The Maybelline beauty product line)
     (VP had
         (NP higher sales)
	 (PP-TMP following
		 (NP a sluggish first half)))
     .))
( (S (PP-LOC In
	     (NP Big Board composite trading))
     ,
     (NP-SBJ-1 Schering-Plough shares)
     (VP fell
         (NP-EXT 75 cents)
         (S-CLR (NP-SBJ *-1)
		(VP to
		    (VP close
			(PP-CLR at
				(NP $ 74.125 *U*))))))
     .))
